Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-methyl-4-(diethyldithiocarbamoyl)cyclophosphamide is a synthetic derivative of cyclophosphamide, likely designed for research into modifications of classic alkylating agents. The structure indicates it is a modified nitrogen mustard, structurally related to cyclophosphamide, which is a prodrug that is metabolized in the liver to active cytotoxic metabolites that alkylate DNA and inhibit replication and transcription, leading to cell death. No evidence of clinical use, commercial development, or established mechanism of action for this exact derivative is found in current biomedical or chemical literature. Its mechanism, where relevant, would be expected to mirror that of other phosphoramide mustards unless a unique property is established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-methyl-4-(diethyldithiocarbamoyl)cyclophosphamide.